Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis

Eileen M Boyle, MD, Brian A Walker, PhD, Dorota Rowczienio, MSc, Christopher P Wardell, PhD, Alexander Murison, PhD, Aneta Mikulasova, M.Sc., Sajitha Sachchithanantham, BSc,MBBS,MRCP,FRCPath,, Anna Baginska, Shameem Mahmood, MRCP. FRCPath, Julian D Gillmore, Helen J Lachmann, MD FRCP, Philip N Hawkins, MD FRCP, FMedSci, Xavier Leleu, MD PhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Ashutosh Wechalekar, MDFRCPath

Blood (2014) 124 (21): 726.

https://doi.org/10.1182/blood.V124.21.726.726

Published: 2014

Journal Articles

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MD, Sajitha Sachchithanantham, MRCP, FRCPath, Marianna Fontana, MD, Shameem Mahmood, MRCP. FRCPath, Darren Foard, RN, Thirusha Lane, RN, Helen J Lachmann, MD FRCP, Julian D Gillmore, MD FRCP, Philip N Hawkins, MD FRCP, FMedSci

Blood (2014) 124 (21): 3485.

https://doi.org/10.1182/blood.V124.21.3485.3485

Published: 2014

Journal Articles

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

Sajitha Sachchithanantham, BSc,MBBS,MRCP,FRCPath,, Ruth M de Tute, Anna Baginska, Christopher Parrish, MD, Shameem Mahmood, MRCP. FRCPath, Andy Rawstron, PhD, Julian D Gillmore, MD FRCP, Helen J Lachmann, MD FRCP, Philip N Hawkins, Roger G Owen, MD, Ashutosh Wechalekar, Dr

Blood (2014) 124 (21): 2073.

https://doi.org/10.1182/blood.V124.21.2073.2073

Published: 2014

Journal Articles

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Shameem Mahmood, MRCP. FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontana, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath

Blood (2013) 122 (21): 1981.

https://doi.org/10.1182/blood.V122.21.1981.1981

Published: 2013

Journal Articles

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Shameem Mahmood, MRCP. FRCPath, Sajitha Sachchithanantham, MRCP. FRCPath, Frank Bridoux, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontanna, MD, Carol Whelan, MD, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath

Blood (2013) 122 (21): 3143.

https://doi.org/10.1182/blood.V122.21.3143.3143

Published: 2013

Journal Articles

Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis

Brian A Walker, PhD, Dorota Rowczienio, MSc, Eileen M Boyle, MD, Christopher P Wardell, PhD, Sajitha Sachchithanantham, MRCP, FRCPath, Anna Baginska, Julian D Gillmore, MD, Shameem Mahmood, MRCP. FRCPath, Helen J Lachmann, MD, FRCP, Philip N Hawkins, Faith E Davies, MD, Gareth J Morgan, MD PhD, Ashutosh Wechalekar, MD, FRCPath

Blood (2013) 122 (21): 3098.

https://doi.org/10.1182/blood.V122.21.3098.3098

Published: 2013

Journal Articles

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Anna Baginska, Dorota Rowczenio, Shameem Mahmood, MRCP, FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath

Blood (2013) 122 (21): 3120.

https://doi.org/10.1182/blood.V122.21.3120.3120

Published: 2013

NARROW

Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only